Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Score 3
1998 pubmed

Direct effects of corticotrophin-releasing hormone on stimulated growth hormone secretion.

Raza. J J; Massoud. A F AF; Hindmarsh. P C PC; Robinson. I C IC; Brook. C G CG

Key Findings

  • CRH pretreatment cuts the GH surge caused by GHRH by about half.
  • The GH‑blocking effect of CRH is independent of ACTH or cortisol levels.
  • Both ACTH and a single dose of hydrocortisone enhance the GH response to GHRH.

Practical Outcomes

  • For biohackers, high stress (which raises CRH) may blunt the effectiveness of GH‑boosting tactics like GHRH peptides. Timing GH‑releasing interventions when you’re relaxed, or after a brief cortisol boost, could improve the GH spike, but chronic cortisol use has other health risks. Consider managing stress and possibly using short‑acting cortisol only in controlled, short‑term experiments.

Summary

The study shows that the stress hormone CRH can directly block the rise in growth hormone (GH) that normally follows a GH‑releasing hormone (GHRH) shot, and this isn’t because CRH raises ACTH or cortisol. In contrast, giving ACTH or a short‑acting cortisol boost actually makes the GH response bigger. The likely reason is that CRH may trigger somatostatin, which shuts down GH release.

Abstract

This study evaluated the effect of corticotrophin-releasing hormone (CRH) on growth hormone releasing hormone (GHRH)-stimulated growth hormone (GH) release in man. Six healthy adult volunteers (age 20-35 years) were studied. On different occasions they each received an intravenous bolus of saline, CRH(1-41) (100 micrograms), adrenocorticotrophic hormone (ACTH) [Synacthen (500 ng/m2)] or hydrocortisone (50 mg), followed 30 minutes later by an intravenous bolus of either GHRH-(1-29)-NH2 (1.0 microgram/kg) or saline. Serum GH concentrations were measured using an immunoradiometric assay, and cortisol concentrations were measured by commercial radioimmunoassay. TSH concentrations were measured using a solid phase immunoradiometric assay kit. Pretreatment with CRH(1-41) attenuated the GH response to GHRH [saline/GHRH-(1-29)-NH2 20.2 +/- 6.2 mU/l; CRH(1-41)/GHRH-(1-29)-NH2 10.9 +/- 2.8 mU/l (P = 0.01)]. This effect was not due to the rise in ACTH or cortisol induced by CRH(1-41), since pretreatment with either ACTH or hydrocortisone significantly augmented the GH response to GHRH-(1-29)-NH2 in the same subjects [ACTH/GHRH-(1-29)-NH2 30.3 +/- 8.8 mU/l (P = 0.01); hydrocortisone/GHRH-(1-29)-NH2 36.4 +/- 11.2 mU/l (P = 0.02)]. Our data suggest that the inhibitory effect of CRH(1-41) on GHRH-(1-29)-NH2-induced GH release is not a result of ACTH or cortisol release but reflects a direct action of CRH on GH secretion, possibly via stimulation of somatostatin release. The acute rise in GH following glucocorticoid administration could be explained in part by a rapid suppression of endogenous CRH.

Study Information

Provider

pubmed

Year

1998

DOI

10.1046/j.1365-2265.1998.3821204.x